Want to track RLMD and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Relmada Therapeutics Inc. (RLMD) Statistics
Valuation metrics
Market Cap 426.9M
Enterprise value 453.33M
Trailing P/E (ttm) -4.82
Forward P/E -17.15
PEG ratio -0.05
Price/Sales (ttm) -
Price/Book (mrq) 2.41
Enterprise Value/Revenue -
Enterprise Value/EBITDA -7.32
Overview
Shares outstanding 104.89M
Float 7.72M
Shares short 5.35M
% Held by insiders 0.03%
% Held by institutions 0.81%
Average volume (10 days) 809.59K
Average volume (90 days) 1.95M
Price summary
52-Week low 1.45
52-Week high 8
Beta 0.73
50-Day moving average 4.87
200-Day moving average 6.2
Dividends and splits
Forward annual dividend rate -
Forward annual dividend yield -
Trailing annual dividend rate -
Trailing annual dividend yield -
5-Year annual dividend yield -
Payout ratio -
Dividend Date -
Ex-Dividend Date -
Last split factor 1:4
Last split Date 30 Sep 2019
Financials
Fiscal year
Fiscal year ends 31 Dec 2025
Most recent quarter (mrq) 31 Mar 2026
Profitability
Profit margin -
Operating margin -
Operational effectiveness
Return on assets -0.28%
Return on equity -0.48%
Income Statement
Revenue (ttm) -
Revenue per share (ttm) -
Quarterly revenue growth (yoy) -
Gross profit (ttm) -
EBITDA -13.86M
Net income to common (ttm) -15.01M
Diluted EPS (ttm) -0.55
Quarterly earnings growth (yoy) -
Balance Sheet
Total cash (mrq) 116.44M
Total cash per share (mrq) 1.94
Total debt (mrq) 110.25K
Total Debt/Equity (mrq) 0.1
Current ratio (mrq) 29.52%
Book value per share (mrq) 1.84
Cash Flow
Cash flow statement -12.09M
Levered free cash flow (LFCF) -7.74M
